SHANDONG BOAN BIOTECH.H 1 (F:UJ9) — Market Cap & Net Worth
Market Cap & Net Worth: SHANDONG BOAN BIOTECH.H 1 (UJ9)
SHANDONG BOAN BIOTECH.H 1 (F:UJ9) has a market capitalization of $538.40 Million (€460.53 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #12147 globally and #1319 in its home market, demonstrating a 3.50% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANDONG BOAN BIOTECH.H 1's stock price €0.74 by its total outstanding shares 622333694 (622.33 Million).
SHANDONG BOAN BIOTECH.H 1 Market Cap History: 2023 to 2026
SHANDONG BOAN BIOTECH.H 1's market capitalization history from 2023 to 2026. Data shows change from $1.50 Billion to $538.40 Million (-23.75% CAGR).
SHANDONG BOAN BIOTECH.H 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANDONG BOAN BIOTECH.H 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of UJ9 by Market Capitalization
Companies near SHANDONG BOAN BIOTECH.H 1 in the global market cap rankings as of May 2, 2026.
Key companies related to SHANDONG BOAN BIOTECH.H 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
SHANDONG BOAN BIOTECH.H 1 Historical Marketcap From 2023 to 2026
Between 2023 and today, SHANDONG BOAN BIOTECH.H 1's market cap moved from $1.50 Billion to $ 538.40 Million, with a yearly change of -23.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €538.40 Million | -12.43% |
| 2025 | €614.80 Million | -20.28% |
| 2024 | €771.23 Million | -48.54% |
| 2023 | €1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of SHANDONG BOAN BIOTECH.H 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $538.40 Million USD |
| MoneyControl | $538.40 Million USD |
| MarketWatch | $538.40 Million USD |
| marketcap.company | $538.40 Million USD |
| Reuters | $538.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more